Professor Dan Chambers

Professor in Thoracic Medicine-Sec

Prince Charles Hospital Northside Clinical Unit
Faculty of Medicine

Overview

Professor Dan Chambers, MBBS(Hons1) MRCP FRACP MD

Daniel.Chambers@health.qld.gov.au

Professor Dan Chambers graduated from UQ in 1993 with the William Nathaniel Robertson Medal and a University Medal. In 2002 he received an MD from the University of Birmingham, UK for his work on the pulmonary biology of nitric oxide. He completed his specialist training in thoracic and general medicine in the UK, with a particular interest in cystic fibrosis, before returning to Australia in 2003. He then returned once again to the UK to complete a Fellowship in lung transplantation at the Freeman Hospital, Newcastle-Upon-Tyne, in 2005.

Dan was awarded FRACP in 2005 and was one of the founding clinicians of the Western Australian Lung Transplant Program where he worked until 2008. Since returning to Queensland, Dan has worked as a Thoracic Transplant Physician at Prince Charles Hospital where he is now a Pre-eminent Specialist. He is Head of Research in the Qld Lung Transplant Service and has established a vibrant independent research program within the UQ Thoracic Research Centre located at Prince Charles Hospital. His research is very translational in nature, with particular interests in pulmonary fibrosis, cellular therapies for lung disease, ex-vivo lung perfusion and the pathogenesis of pulmonary fibrosis and chronic lung allograft dysfunction. Together with industry and academic collaborators, he has successfully translated promising preclinical data into first-in-man studies of new therapies for idiopathic pulmonary fibrosis, lung transplantation, pulmonary hypertension, silicosis and drug-resistant viral infection. He is an internationally recognised authority in the fields of lung fibrosis, cell therapy for lung disease and lung transplantatio. He is the first Australian to direct to International Adult Lung Transplant Registry. He has attracted over $15 million to support his research program and has authored over 100 original papers and book chapters.

Dan was a key member of the team which pioneered ex-vivo lung perfusion to resuscitate marginal donor organs in Australia in 2011. He has used this technology to improve the safety of early phase human trials, and in so doing conceived and developed guidelines for the use of donated human lungs for research in Australia, a document now endorsed by the Transplantation Society of Australia and New Zealand and utilised around the country. In 2013 and 2014 he was a member of the International Society for Heart and Lung Transplantation Annual Scientific Meeting Programming Committee. He is Co-Chair of the Scientific Programming & Education Committee, Transplantation Society of Australia & New Zealand and was Chair of the Organising Committee for the 2015 Annual Scientific Meeting. He is a regular reviewer for all of the highest ranked journals in respiratory and transplantation medicine and is on the Editorial Board of the European Respiratory Journal.

Research Interests

  • Lung transplantation
  • Lung fibrosis
  • Stem cells
  • Cellular therapy

Research Impacts

Professor Chambers is a recognised thought leader in the fields of lung fibrosis, lung cell therapy and lung transplantation. His contributions to these fields have translated into improvements in the management of a wide range of serious lung diseases including silicosis, lung transplant rejection, lung fibrosis and grown up neontal lung disease. His contribution to knowledge in these diverse areas has been recognised in his apointment to several governmental panels including the Biologicals Advisory Committee (Therapeutic Goods Administration, 2017-2019), the Interim Advisory Panel of the Notifiable Dust Lung Disease Register (Qld Government, 2020-2021) and the Virtual Cross Match Working Group (Organ and Tissue Authority, 2020-2021). He has either chaired or contributed to committees and working groups which have developed international position statements or guidelines in diverse areas of advanced lung disease including the management of fungal infection, conduct of bronchoalveolar lavage, and donor and recipient lung transplant management, and national guidlines in these areas and in the diagnosis and management of interstitial lung disease. He runs one of the world's largest clincial trial centres focussed on interstitial lung disease, and has collaborated with multiple academic and industry partners to bring new tretaments to patients with serious lung disease. His work is regularly featured in the Australian media.

Publications

View all Publications

Supervision

View all Supervision

Publications

Featured Publications

Book Chapter

  • Chambers, Daniel C. (2018). Chronic lung allograft dysfunction: phenotypes and the future. Essentials in lung transplantation. (pp. 119-129) edited by Allan R. Glanville. Cham, Switzerland: Springer International Publishing. doi: 10.1007/978-3-319-90933-2_11

  • Chambers, Daniel (2015). Mesenchymal stromal cell-based therapies for lung disease. Stem Cells in the Lung: Development, Repair and Regeneration. (pp. 225-242) edited by Ivan Bertoncello. Heidelberg, Germany: Springer Spektrum. doi: 10.1007/978-3-319-21082-7_14

  • Chambers, D. and Hopkins, P. (2012). Pulmonary clinical applications for mesenchymal stem cells. Mesenchymal stem cell therapy. (pp. 87-99) edited by Lucas G. Chase and Mohan C. Vemuri. Totowa, NJ USA: Humana Press. doi: 10.1007/978-1-62703-200-1_5

  • Chambers, Daniel C. and Sole, Amparo (2011). Mold infections in cardiothoracic transplantation. Diagnosis and Management of Infectious Diseases in Cardiothoracic Transplantation and Mechanical Circulatory Support. (pp. 195-209) edited by Martha L. Mooney, Margaret M. Hannan, Shahid Husain and James K. Kirklin. Addison, TX, United States: International Society of Heart and Lung Transplantation.

  • Hodge, Greg, Hodge, S., reynolds, P., Chambers, D. and Holmes, M. (2009). Leucocyte intracellular cytokines in lung transplant patients : A more physiological indicator of immunosuppression than plasma drug levels. Immunosuppression : New research. (pp. 91-115) edited by Charles B. Taylor. New York, NY, United States: Nova Biomedical Books.

Journal Article

Conference Publication

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

  • Doctor Philosophy — Associate Advisor

    Other advisors:

  • Doctor Philosophy — Associate Advisor

Completed Supervision